Sunitinib Malate

Licensed by Pfizer Catalog No.S1042

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 97 In stock
USD 147 In stock
USD 447 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 42 Publications

12 Customer Reviews

  • PDGF-AA induces Ezh2 expression and proliferation in juvenile islets but not in adult islets. Western immunoblots of indicated islet proteins from 3 week or 9 month-old WT islets 2 days after exposure to PDGF-AA alone, or PDGF-AA plus RTK inhibitors Sunitinib.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

    Assessment of effects on human juvenile or adult islets after exposure to PDGF-AA (50 ng/ml) for 2 days, with or without Sunitinib (2 uM) or U0126 (10 uM)co-treatment. Average percentage of BrdU+ insulin+ cells was morphometry from sectioned islets immunostained for insulin (green), glucagon (white) and BrdU (red). n = 3-6 independent experiments.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Sunitinib Malate purchased from Selleck.

    A, Tumor growth curves from the initial sunitinib drug trials, with endpoint set at 1,300 mm3 (mean ± SEM). Measurements began one week after tumor inoculation and on the day sunitinib treatment began. Subsequent experimental endpoints were set on the basis of these growth curves and their intersections with this data are shown. B, Histogram plot showing the distribution of tumor sizes at day 8 of treatment. Sunitinib-treated tumors exceeding 250 mm3 in size were identified as falling into the nonresponsive cohort. Sunitinib treatment significantly retards growth of responsive tumors.

    Cancer Res, 2017, 77(4):1008-1020 . Sunitinib Malate purchased from Selleck.

  • Sunitinib decreases FLT-3 and RET phosphor ylation but increases ERK phosphorylation in a time-dependent manner. H295R and SW13 cells were treated with sunitinib (10 nM) for various time points as indi-cated. Cell lysates were prepared and phospho-FLT-3, RET, and ERK levels were monitored by Western Blot-ting. Re-probing against FLT-3, RET, and ERK was done to ensure equal protein loading.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

    Sunitinib or PD98059 decreases cell proliferation in a dose-dependent manner. H295R and SW13 cells were treated with various concentration of sunitinib or PD98059 for 48 hours as indicated. Treated cells were subjected to the MTS proliferation assay. Similar experiments were repeated 3 times. Histograms represent relative % of OD490 nm absorbance (* P < .05). All data are relative multiples of expression compared with untreated cells. The data are representative of three experiments and are expressed as the mean ?SE.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

  • Autophagic activation in sunitinib- and sorafenib- but not AZD6244-treated cells. Medullary thyroid cancer-1.1 (MTC-1.1; A) and TT ( B) cells were treated with dimethyl sulfoxide (DMSO), sunitinib (50 nM), sorafenib (10 nM), AZD6244 (30 nM), or everolimus (20 nM) for 48 hours. Cell lysates were prepared, and light chain 3 (LC3)-I and -II cleaved caspase-3 protein levels were monitored by Western blotting. Reprobing against actin was per formed to ensure equal protein loading. ( C ) MTC-1.1 and TT cells were transiently transfected with autophagy protein 5 (Atg-5) small inter fering RNA. Transfection with scrambled small inter fering RNA was used as a control. After transfection, cells with and without Atg-5 knockdown were exposed to DMSO or 20 nM of everolimus for 48 hours. Cell lysates were pre- pared and LC3-I and -II protein expression levels were monitored by Western blotting. Reprobing against Atg-5 was per formed to monitor Atg-5 knockdown efficiency. Reprobing against actin was per formed to ensure equal protein.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

    Autophagy inhibition blocks the antiproliferative effects of sunitinib and sorafenib but not AZD6244. Medullary thyroid cancer–1.1 (MTC-1.1) and TT cells were transfected transiently with scrambled or autophagy protein 5 (Atg-5) small inter fering RNA. After transfection, cells with and without Atg-5 knockdown were exposed to sunitinib (50 nM), sorafenib (10 nM), and AZD6244 (30 nM) for 48 hours. Treated cells were subjected to a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium proliferation assay. Similar experiments were repeated 3 times. Histograms represent the relative percent of OD490 nM absorbance. The asterisk indicates significance versus scrambled small inter fering RNA–treated control ( P < .05). All data are relative multiples of expression compared to untreated cells. The data are representative of 3 experiments and are expressed as the mean ± the standard error.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

  • Sunitinib limits the colonial growth of HT-29 by downregulating HIF-1a. (A) The number and size of colonies formed in soft agar. The numbers of small colonies (<50 μm diameter) were not different among conditions of a serial concentration of sunitinib. On the contrary, large colonies (>50 μm diameter) disappeared after incubation with sunitinib. Each point represents the mean and SD from four separate experiments. (B) HIF-1a expression and hypoxia within HT-29 colony. After colonies grew for 4 weeks, HIF-1a and hypoxia were visualized by immunofluoroscence staining. Bar = 20 μm.

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    2. Sunitinib downregulates HIF-1a. (A) Dose-dependent repression of HIF-1a protein level by sunitinib in HT-29. HT-29 cells were incubated under normoxic (N) or hypoxic (H) conditions in the presence of sunitinib for 24 h. HIF-1a and ARNT proteins in total cell lysates were analyzed by Western blotting. (B) Sunitinib attenuates the hypoxic induction of HIF-1 target genes. RNAs were isolated from HT-29 cells subjected to normoxia (N) or hypoxia (H) in the presence of sunitinib for 16 h. The mRNAs of HIF-1a and its target genes were analyzed by RT-PCR and autoradiography. PGK1 indicates phosphoglycerate kinase 1; PDK1, pyruvate dyhydrogenase kinase 1; CAIX, carbonic anhydrase IX. (C) Sunitinib-induced HIF-1 inhibition. Epo-enhancer and b- galactosidase reporter plasmids were co-transfected into HEK293 cells. After 16 h incubation, luciferase and b-galactosidase activities were measured. *P < .05 versus the hypoxic control.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

  • Sunitinib inhibits 50-UTR-dependent translation of HIF-1a. (A) 50 cap-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the tk promoter and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 lg per 100-mm dish) and the b-gal plasmid (4 μg). After 16 h incubation under normoxic or hypoxic conditions with sunitinib, cells were lysed and subjected to luciferase assay. *P < .05 versus the hypoxic control. (B) IRES-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the GFP gene and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 μg) and the b-gal plasmid (4 μg). *P < .05 versus the hypoxic control. (C) Sunitinib inhibits phosphorylation of Akt. After 8 h incubation under hypoxic condition with sunitinib, HT-29 cells were lysed and subjected to Western blotting. (D) Sunitinib suppresses HIF-1a in VHL-null RCC4 cells. VHL (-/-) RCC4 cells were incubated under normoxic conditions sunitinib for 8 h, and HIF-1a in total cell lysates was analyzed by Western blotting.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    Experimental layout for VEGF signaling blocking and LCMV infection in WT mice. Mice received two injections on day 0 and 3 p.i. of Abs as described in Material and Methods, or daily gavage of the VEGFR/PDGFR-inhibitor sunitinib. Inguinal LN volume on day 0 (D0) or day 8 (D8) p.i. after treatment of mice with control Ig or anti-VEGFR2, anti-VEGF-A Abs or sunitinib. Pooled from 1-2 independent experiments with 3-5 mice per treatment. D. Total HEV length on day 0 (D0) or day 8 (D8) p.i. as in C. No significant difference was found in C and D between day 8 control Ig and Ab- or inhibitor-treated values (One-way ANOVA).

    AACR Sunitinib Malate purchased from Selleck.

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
2 nM 80 nM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 MljNT4lv[XOnIFHzd4F6 MWrJcohq[mm2aX;uJI9nKFCGR1[tbY5lfWOnZDDCdoRWKGmwY3;ydI9z[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEC3JO69VQ>? Mnm2NVI3PDZyMUm=
3T3 NUXQOpdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPkPIFjUW6qaXLpeIlwdiCxZjDQcIF1\WyndD3k[ZJqfmWmIHfyc5d1cCCoYXP0c5IhcW6mdXPl[EA{XDNiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjBzIN88US=> M{\0TFEzPjR4MEG5
3T3 MVrGeY5kfGmxbjDBd5NigQ>? NEn3U4FKdmirYnn0bY9vKG:oIG\hd4N2dGG{IHXu[I91cGWuaXHsJIdzd3e2aDDmZYN1d3JicnXj[ZB1d3Jid3n0bEBKSzVyIH;mJFAvODVizszN MWixNlY1PjBzOR?=
3T3 MVHLbY5ie2ViQYPzZZk> MlzQNlAhdWmw NXTqWnpQTE2VTx?= MkXRR4VtdHWuYYKgbY5pcWKrdHnvckBw\iCYRVfGJIlv\HWlZXSgbJVu[W5iS1TSJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMkKg{txO MV6xOlE3OjByOB?=
NIH3T3 MmXUT4lv[XOnIFHzd4F6 MXeyNEBucW5? NGnRRW9FVVOR M1zUO4lvcGmkaYSgbJVu[W5iS1TSJItqdmG|ZTDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMEG4JO69VQ>? NGPlVVEyPjF4MkCwPC=>
A549 NIH5PJJHfW6ldHnvckBCe3OjeR?= NXL3eoR1TE2VTx?= MkjvTY5pcWKrdHnvckBw\iClLV3leEBl\XCnbnTlcpQhUEeILXnu[JVk\WRiaIXtZY4hSTV2OTDj[YxtKG2rZ4LheIlwdiC5aYToJGlEPTBib3[gNkDPxE1? NHPEbpgyQDR|NEG0OS=>
DU145 M3;WSWZ2dmO2aX;uJGF{e2G7 NYfxZmJLTE2VTx?= NHrMOnFKdmirYnn0bY9vKG:oIHOtUYV1KGSncHXu[IVvfCCKR1[tbY5lfWOnZDDoeY1idiCGVUG0OUBk\WyuIIPjZZR1\XKrbnege4l1cCCLQ{WwJI9nKDFyIN88US=> M3raS|E5PDN2MUS1
KB3-1 NXfqc5FkS3m2b4TvfIlkKEG|c3H5 MoHUO|IhcA>? NGrMPJRFVVOR M1eySWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHAu\3BvbnXnZZRqfmViS1KtN{0yKGOnbHzzJJdqfGhiSVO1NEBw\iB{LkOg{txO M3znXVE6Ozl5M{Ky
KBV1 MonqR5l1d3SxeHnjJGF{e2G7 MXq3NkBp MVrEUXNQ NGXLZYlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRNWeueXPvdJJwfGWrbj3lfJBz\XO|aX7nJGtDXjFiY3XscJMhf2m2aDDJR|UxKG:oIESuNUDPxE1? NHnEOIEyQTN7N{OyNi=>
A375 M3TtOmN6fG:2b4jpZ{BCe3OjeR?= MmDpO|IhcA>? MX;EUXNQ NFzHNXVKSzVyPUWuOEDPxE1? MWixPVY2PDRyOB?=
RS4-11 NYjXVXBoTnWwY4Tpc44hSXO|YYm= M3G4[FIhcA>? MUHJcohq[mm2aX;uJI9nKE[OVEOgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFk6KM7:TR?= M4HlcVE6PjV2NEC4
RS4-11 MWfGeY5kfGmxbjDBd5NigQ>? NV;PXld2OiCq NWm5VI0{UW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDteZRidnRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yM{Sg{txO MXmxPVY2PDRyOB?=
Sf9 MlfzT4lv[XOnIFHzd4F6 MlPtN|AhdWmw M3TNNmlvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDWSWdHWiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvOTh3IN88US=> M2rSb|E6QDV2MEWx
Ba/F3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILzRoU4OiCq MWPJR|UxRTFwMjFOwG0> NUnCN4NZOjBzMUewNFQ>
BaPTC2 M4[0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn3[2JsPzJiaB?= MoTjTWM2OD1yLkKyJO69VQ>? NG\JPIgzODFzN{CwOC=>
Sf9 MWTGeY5kfGmxbjDBd5NigQ>? MVixJIg> M{TWSmROW09? NI[4dJNKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjpd{11[WepZXSgVmVVKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU4{KM7:TR?= NGDjfHUzODFzN{CwOC=>
H4 MVfDfZRwfG:6aXOgRZN{[Xl? MUmxNEDPxE1? MkH3WI95cWOrdImgbY4hcHWvYX6gTFQh[2WubIO= Mor2NlA{PTB6ME[=
SF-539 NF;pZoRMcW6jc3WgRZN{[Xl? M4nrW|M{OyEQvF2= NILjbo83OCCvaX6= MlHJSG1UVw>? NXn4e5NtUW6qaXLpeIlwdiCxZjDQSGdHWmKndHGgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAyOi5{IN88US=> NWDSXmQ2OjB2MEO3NFA>
U251 M{LKPWtqdmG|ZTDBd5NigQ>? MYKzN|Mh|ryP MWK2NEBucW5? NYLm[3VETE2VTx?= M{SwXmlvcGmkaYTpc44hd2ZiVlXHSnIzKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMUiuPUDPxE1? M{PQU|IxPDB|N{Cw
A431 NIjndFBMcW6jc3WgRZN{[Xl? MUjJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEzNjJizszN M1zhXFIxPTV6MEey
A431 M2q1c2tqdmG|ZTDBd5NigQ>? M3WwbmlvcGmkaYTpc44hd2ZiVlXHSnIzKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNVgvQSEQvF2= M1Xz[FIxPTV6MEey
HepG2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nFflczKGh? NGDzem1KSzVyPUOuPFEh|ryP M2TUWlIxPTdyNUK2
Kasumi-1 NXXZRYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj3XIFmPzJiaB?= NUizXIFNUUN3ME2wMlAyPiEQvF2= MnPPNlA2PzB3Mk[=
RS4-11 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm1N244OiCq NEjoTZlKSzVyPUGg{txO M1W5ZlIxPTdyNUK2
THP1 M1HkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfaO|IhcA>? MV3JR|UxRTBwNTFOwG0> M2DtdlIxPTdyNUK2
Kasumi-1 M13VemZ2dmO2aX;uJGF{e2G7 MoHZTY5pcWKrdHnvckBw\iClLVvpeEBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAyPSEQvF2= NX7Cc49LOjB6M{OwN|k>
A549 NEfSSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKxOkBp M1rjc2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIO= M4X1d|IyPDVyNE[z
HL60 MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixOkBp NFWwepBCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzz NHjKcGwzOTR3MES2Ny=>
HUVEC M2nMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH3NVYhcA>? NH:yb4dKdmirYnn0bY9vKG:oIG\FS2YucW6mdXPl[EBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIEKuO|Uh|ryP MVeyNVQ2ODR4Mx?=
HUVEC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnNNVYhcA>? NV;VWHdzUW6qaXLpeIlwdiCxZjDiSmdHNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjC0MlA1KM7:TR?= M162eVIyPDVyNE[z
IM9 NE\NTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfVNVYhcA>? MYnBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCLTUmgZ4VtdHN? Mn;UNlE1PTB2NkO=
K562 M13vRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PscFE3KGh? MUPBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy| NVTLOWo{OjF2NUC0OlM>
MDA-MB-231 NGr2dFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjMNVYhcA>? MWfBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{ NID4OnczOTR3MES2Ny=>
H460 M1fMXWN6fG:2b4jpZ{BCe3OjeR?= MlTyO|IhcA>? M1zKVWlEPTB;Mj63JO69VQ>? NFzBWHczOTZ{MUi4NC=>
SMMC7721 NVe5OW5tS3m2b4TvfIlkKEG|c3H5 M2LTcFczKGh? MU\JR|UxRTZwNEeg{txO M{e1fVIyPjJzOEiw
WI38 M4nQb2N6fG:2b4jpZ{BCe3OjeR?= MX23NkBp M3vZcmlEPTB;OD61OkDPxE1? MoHjNlE3OjF6OEC=
HEK293 MYLLbY5ie2ViQYPzZZk> MmXTNVAxKG6P MonyNUBp MmTB[I9meyCwb4SgbY5pcWKrdDDWSWdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiCxZjD0fZJwe2mwZTCxNVc2KHKnc3nkeYUhd25iVlXHSnIzKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJM> MUiyNVg5PTJ6Nx?=
HUVEC MYTGeY5kfGmxbjDBd5NigQ>? M3nHNVEh|ryP NXS0PVVxOjRiaB?= NFLZ[m5CdnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCYRVfGMYlv\HWlZXSgZ4VtdCCvaXfyZZRqd25? M1H2elIyQTZ|M{C1
HUVEC NH\2b4lHfW6ldHnvckBCe3OjeR?= NHTxUVQyKM7:TR?= NVnaR3N6OSCq MVPJcohq[mm2aX;uJI9nKEWUSzDwbI9{eGixconsZZRqd25iYYSgWIhzOjB{L2T5dlIxPCCrbjDWSWdHNXO2aX31cIF1\WRiSGXWSWM> MVKyNVk3OzNyNR?=
HUVEC MoXlSpVv[3Srb36gRZN{[Xl? MlPRNUDPxE1? Mn\mNUBp NXHq[WpkUW6qaXLpeIlwdiCxZjDlUm9UKHCqb4PwbI9zgWyjdHnvckBifCCVZYKtNVE4OiCrbjDWSWdHNXO2aX31cIF1\WRiSGXWSWM> NUnX[5Y1OjF7NkOzNFU>
HUVEC MUXLbY5ie2ViQYPzZZk> NXXzW2JMOSEQvF2= NHrKbmsyKGh? NFjDWIJKdmirYnn0bY9vKG:oIG\FS2ZTOiCyaH;zdIhwenmuYYTpc44h[XRidInyMVEyPzViaX6gWmVITi2|dHnteYxifGWmIFjVWmVE MljVNlE6PjN|MEW=
HUVEC NXnhRXF6TnWwY4Tpc44hSXO|YYm= MVKxJO69VQ>? NVnRTXdkOSCq M3jq[IRw\XNibn;0JIlvcGmkaYSgRWtVKHCqb4PwbI9zgWyjdHnvckBifCCVZYKtOFc{KGmwIG\FS2Yue3SrbYXsZZRm\CCKVW\FRy=> MofzNlE6PjN|MEW=
HL60 NFz4dYREgXSxdH;4bYMhSXO|YYm= M3jhSFUxKM7:TR?= MoTNOFghcA>? NIDiXXFFVVOR NYHsdWRtUUN3ME2xOU42KM7:TR?= M3fhN|IzODF7MUi4
K562 M1f5dGN6fG:2b4jpZ{BCe3OjeR?= MnHQOVAh|ryP M1;VW|Q5KGh? Mo[4SG1UVw>? MWLJR|UxRTJzLkmg{txO MYKyNlAyQTF6OB?=
PC3 M{XlPWN6fG:2b4jpZ{BCe3OjeR?= NIXiNoQ2OCEQvF2= NVHjXGN2PDhiaB?= Mme5SG1UVw>? NGLxSIxKSzVyPUK1MlEh|ryP MYWyNlAyQTF6OB?=
SF-539 NHOwZZhMcW6jc3WgRZN{[Xl? MnzVN|M{KM7:TR?= Moe0OlAhdWmw M1;pO2lvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIIT5do9{cW6nIHvpcoF{\SCjY4Tpeol1gSCrbjDQSGdHNUKELYP0bY12dGG2ZXSgbJVu[W5iU1[tOVM6KGOnbHzzJJdqfGhiSVO1NEBw\iBzMj6yJO69VQ>? NW\3N2JOOjJ{MES3OFE>
HAEC MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1WxN|ExOCEQvF2= NYLoNmN3PzJiaB?= NYfmfodPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIRWVEKGOnbHzzJIV5eHKnc4PpcochXkWJRmKge4l1cCCLQ{WwJI9nKDBwMTFOwG0> MoXrNlI1PDR4N{m=
HT-29 NEDsU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNFAh|ryP NIX1eXE4OiCq M4qxS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOg[ZhxemW|c3nu[{BXTUeIUjD3bZRpKEmFNUCgc4YhOC5|MzFOwG0> MYiyNlQ1PDZ5OR?=
MV4-11 NFLBW4ZEgXSxdH;4bYMhSXO|YYm= NW\2[5k2PzJiaB?= NI\POIdKSzVyPUCuNFA{KM7:TR?= MoDaNlI1PTJ3MUi=
HepG2 MVPDfZRwfG:6aXOgRZN{[Xl? NVrveWpIPDhiaB?= NWDlWpgzUUN3ME2xN{4zPCEQvF2= MXqyNlQ5OzZyOB?=
PC9 MWDDfZRwfG:6aXOgRZN{[Xl? Mo\XOFghcA>? M3PCOmlEPTB;MUCuPVch|ryP MlrmNlI1QDN4MEi=
CAKI-1 NH2zfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq0TJcyODBizszN M1;nRVQ5KGh? MVHEUXNQ MWnHTVUxRTBwNkOg{txO M3TvdlIzPTZyNkK3
EKVX Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TG[lExOCEQvF2= NV[1O2U3PDhiaB?= M3W0XmROW09? NIixbopIUTVyPUeuPUDPxE1? NIXhZpgzOjV4ME[yOy=>
MCF7 NFPobYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfMW2wyODBizszN NGjifJc1QCCq MYjEUXNQ M{e1cWdKPTF;MjFOwG0> MnPnNlI2PjB4Mke=
MDA-MB-435 NEDLVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\Yc|ExOCEQvF2= M{TIWVQ5KGh? NUDpcYlzTE2VTx?= NYG2cmxrT0l3Mk2yJO69VQ>? MYOyNlU3ODZ{Nx?=
OVCAR3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofjNVAxKM7:TR?= MU[0PEBp MUnEUXNQ MXnHTVU{RTNwMjFOwG0> MWqyNlU3ODZ{Nx?=
SNB19 NUn4b4RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fn[|ExOCEQvF2= M{XpbVQ5KGh? MUTEUXNQ MULHTVU1RTFyIN88US=> MoD6NlI2PjB4Mke=
SW620 NFXLdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnpNVAxKM7:TR?= MnvZOFghcA>? M1;OZmROW09? NF36bYJIUTV3PUGuN{DPxE1? M3rVflIzPTZyNkK3
TK10 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPxZpUyODBizszN MlryOFghcA>? MkWxSG1UVw>? NELDZmNIUTV4PU[uN{DPxE1? NHiwTJAzOjV4ME[yOy=>
UACC257 NXTBS2ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[3UnlSOTByIN88US=> MmeyOFghcA>? NULle2h1TE2VTx?= M2S3bGdKPTd;NDFOwG0> MXmyNlU3ODZ{Nx?=
HAEC NVT0fIxTS3m2b4TvfIlkKEG|c3H5 MVGxNFAh|ryP NYnsfINLPzJiaB?= M4j4dWROW09? MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBXTUeIUjDlfJBz\XO|aX7nJGhCTUNid3n0bEBKSzVyIH;mJFAvOSEQvF2= NGiyU3EzOzF|MUW0NS=>
HT-29 NIrOfotEgXSxdH;4bYMhSXO|YYm= MnPINVAxKM7:TR?= M2P1XlczKGh? NY\NRpZvTE2VTx?= NYGwZ3hqS3m2b4TvfIlkcXS7IHHnZYlve3RiVlXHSnIh\XiycnXzd4lv\yCqdX3hckBJXC1{OTDj[YxteyC5aYToJGlEPTBib3[gNE4{OyEQvF2= MmnyNlMyOzF3NEG=
HCT116 M4CxNGZ2dmO2aX;uJGF{e2G7 M{jlTVI1KGh? M1X2NGROW09? MYrBcpRqdWmpcnH0c5J6KGGldHn2bZR6KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2WubDDtbYdz[XSrb36= M2\4O|I{OTV|MkCw
HUVEC NYjoNpFTTnWwY4Tpc44hSXO|YYm= M2LmUlIh|ryP MmrmNVghcA>? MoXiSG1UVw>? NG\6fXVCdnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQ4OgeY5l\XJiaInwc5hq[yClb37kbZRqd25iYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dXLlJIZwem2jdHnvci=> M{[1VVI{OTV|MkCw
ACHN M1XWdGN6fG:2b4jpZ{BCe3OjeR?= MWW2JIQ> Mn7qTWM2OD1{LkWg{txO MmfwNlM{PjBzMES=
A498 NYK5V|Y{S3m2b4TvfIlkKEG|c3H5 MnzqNVAxKM7:TR?= M{HiZVczKGh? MWLEUXNQ NIXoU4xKSzVyPUSuN{DPxE1? M{Lxc|I{PDh7NkK2
HUVEC NIT0VmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGzJO69VQ>? M1[zeFI1KGh? MYXEUXNQ M3KzNGFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiVlXHSk1qdmS3Y3XkJJR2[mViZn;ycYF1cW:wIIfpeIghTUN3MDDv[kAxNjZ2NTFOwG0> MmW3NlM2QDN7MUG=
HUVEC MnS1T4lv[XOnIFHzd4F6 M3:zfVIxOCEQvF2= MoDDSG1UVw>? MUjJcohq[mm2aX;uJI9nKF[HR1\SNkBxcG:|cHjvdplt[XSrb36gbY4h\3Kxd4ToJIZi[3Sxcj3zeIlufWyjdHXkJGhWXkWF MXWyN|U5OzlzMR?=
HUVEC NWLzcHFsU2mwYYPlJGF{e2G7 M4S3[lIxOCEQvF2= M4PRSmROW09? NHPzWGxKdmirYnn0bY9vKG:oIG\FS2ZTOSCyaH;zdIhwenmuYYTpc44hcW5iZ4Lve5RpKG[jY4Tvdk1{fGmvdXzheIVlKEiXVlXD NH6xT|EzOzV6M{mxNS=>
A549 MnHmR5l1d3SxeHnjJGF{e2G7 NID1bpg4OiCq NXvpc4FGTE2VTx?= NEi2[VFKSzVyPUKuOFQh|ryP Mnq3NlM3ODJ2NEG=
HCT116 MYTDfZRwfG:6aXOgRZN{[Xl? MoDsO|IhcA>? NHPodGZFVVOR MoizTWM2OD12LkexJO69VQ>? MYmyN|YxOjR2MR?=
MCF7 NFzyNlJEgXSxdH;4bYMhSXO|YYm= NVPJOJdoPzJiaB?= MVXEUXNQ MoTnTWM2OD14LkK5JO69VQ>? MVmyN|YxOjR2MR?=
BGC NVT4VVc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf3WHc4OiCq Mn3jSG1UVw>? MULJR|UxRTRwN{ig{txO M13qdFI{QTl7MESw
BxPC3 M1XXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD6cXY4OiCq MmC2SG1UVw>? NIHQSnZKSzVyPUOuOlMh|ryP MX6yN|k6QTB2MB?=
HT-29 MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID6bXM4OiCq MUnEUXNQ MmnUTWM2OD1zLkS3JO69VQ>? MnvoNlM6QTlyNEC=
T24 NXvYcGtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWC3NkBp NEDucmFFVVOR M4G1NGlEPTB;Mj60OEDPxE1? NIXXZpQzOzl7OUC0NC=>
4T1 NVr6XFVMS3m2b4TvfIlkKEG|c3H5 M3Xi[lczKGh? M{\jcmROW09? MV3JR|UxRTBwMEG2JO69VQ>? MWGyOFg6ODZ3Mh?=
MCF7 MXvDfZRwfG:6aXOgRZN{[Xl? NFHN[I84OiCq M1X6cGROW09? NYLaR2ZGUUN3ME2wMlAzPzFizszN NVviZll3OjR6OUC2OVI>
MCF7 NV[yS|RqS3m2b4TvfIlkKEG|c3H5 NHW0eJk4OiCq NWS5Z2poTE2VTx?= MnPhTWM2OD1yLkCyPVMh|ryP MkHFNlQ5QTB4NUK=
MDA-MB-231 Mo\PR5l1d3SxeHnjJGF{e2G7 MoPhO|IhcA>? M4LB[WROW09? M{XGRWlEPTB;MD6wNlI{KM7:TR?= MnzONlQ5QTB4NUK=
MDA-MB-435 M{f4[WN6fG:2b4jpZ{BCe3OjeR?= NUjlXW1ZPzJiaB?= NEHzV5JFVVOR MVnJR|UxRTBwMEC5O{DPxE1? NEKzeHkzPDh7ME[1Ni=>
MDA-MB-468 NFTDblJEgXSxdH;4bYMhSXO|YYm= MkjUO|IhcA>? MVnEUXNQ NECw[WlKSzVyPUCuNFA3OSEQvF2= Ml74NlQ5QTB4NUK=
A431 MonyT4lv[XOnIFHzd4F6 MmH6NVAh|ryP MUOxJIg> M4XmNmROW09? MVvJcohq[mm2aX;uJI9nKEWJRmKge4l1cCCLQ{WwJI9nKDBwMUeyNUDPxE1? NXT0UoNxOjR6OUC2OVI>
SH-SY5Y MknDT4lv[XOnIFHzd4F6 NYjXenU4OTBizszN MonmNUBp NFntbotFVVOR NInpOYRKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTD3bZRpKEmFNUCgc4YhOC5yOEOxJO69VQ>? MlTDNlQ5QTB4NUK=
U251 NYrwd|I6U2mwYYPlJGF{e2G7 MXSxNEDPxE1? M2jCSlEhcA>? MmKzSG1UVw>? M1;jT2lvcGmkaYTpc44hd2ZiVlXHSnIzKHerdHigTWM2OCCxZjCwMlAyQDlizszN MlfMNlQ5QTB4NUK=
Bel7402 NGr0NJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrMNoYyPzJiaB?= M4mybGROW09? NWnUUo1rUUN3ME2yMlY4KM7:TR?= M1\UbFI1QTB2OU[x
HK2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTvTHBFPzJiaB?= M3TFO2ROW09? NXTMVJRIUUN3ME21Mlg2KM7:TR?= NH3LRXkzPDlyNEm2NS=>
LO2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP6O3o4OiCq NWH2XmNzTE2VTx?= NHm2enZKSzVyPUG5Mlk{KM7:TR?= NXXlOYpZOjR7MES5OlE>
MV4-11 NYTSVlFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXuRmp7PDhiaB?= M1eweWROW09? NYHpSFJzUUN3ME2wMlAxOyEQvF2= NYW0[GlQOjR7MES5OlE>
NCI-H3122 NIjocWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXsO|IhcA>? MXfEUXNQ NGfRbGJKSzVyPUCuPFMh|ryP NGfSfo4zPDlyNEm2NS=>
NCI-H460 MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvjO|IhcA>? NF3zWmRFVVOR NUXuOZJyUUN3ME20MlMyKM7:TR?= M3noW|I1QTB2OU[x
NCI-H526 NW\YNGZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXDW45iPzJiaB?= NXLrOWk3TE2VTx?= NYK1eXVKUUN3ME2xMlAyKM7:TR?= MVGyOFkxPDl4MR?=
TT M1vaU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy4PXZmPzJiaB?= NU[1c41TTE2VTx?= MV7JR|UxRTBwMESg{txO NWDlOo1SOjR7MES5OlE>
EoL-1-cell MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XIRmlEPTB;MT62OEBxVQ>? NIKwbJJUSU6JRWK=
MV-4-11 M2XCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP6TWM2OD1{N{KgdG0> NVS1S2U3W0GQR1XS
NOS-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PPeWlEPTB;MUWuN{BvVQ>? MnP0V2FPT0WU
CGTH-W-1 NELuXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTNyLkm0JI5O MmLwV2FPT0WU
MONO-MAC-6 NHvVVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTLT2hKSzVyPUOzMlghdk1? NGO2ZoVUSU6JRWK=
ALL-PO MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3wTWM2OD15OT64PUBvVQ>? M1GyWnNCVkeHUh?=
NKM-1 M2rGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTl6LkWyJI5O NYPZVYRDW0GQR1XS
KM12 M2P6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLRVJp5UUN3ME2zOVAvOTRibl2= NWrweldvW0GQR1XS
TE-15 M1PWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvJTVhjUUN3ME21NFcvPjFibl2= NIW5UXpUSU6JRWK=
697 M3S2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTZzND6yOUBvVQ>? M1TiTXNCVkeHUh?=
MOLT-16 NUfpToZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DVTWlEPTB;NkOxMlMzKG6P MYfTRW5ITVJ?
GB-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTdzMD6yN{BvVQ>? MWrTRW5ITVJ?
TE-12 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn1TWM2OD16MESuOVUhdk1? M3X1THNCVkeHUh?=
ES6 M33lUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv5PZhqUUN3ME25PFEvODZibl2= MVjTRW5ITVJ?
LC-2-ad MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:4TWM2OD1zLkGxOFA4KM7:TR?= MXXTRW5ITVJ?
BL-70 M2G4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrEN5o{UUN3ME2xMlEyQDR4IN88US=> NGnnb49USU6JRWK=
ETK-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LnfmlEPTB;MT6yPFU5KM7:TR?= NUX6dlBXW0GQR1XS
A4-Fuk M4HDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrmTWM2OD1zLkO0NVQyKM7:TR?= NI\veHhUSU6JRWK=
OCI-AML2 NIfqOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwM{[4OVEh|ryP M4nOV3NCVkeHUh?=
SIG-M5 NXTXd4V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7IT49KSzVyPUGuN|cxODlizszN MlLJV2FPT0WU
NCI-SNU-16 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnntTWM2OD1zLkS2OFg3KM7:TR?= MX;TRW5ITVJ?
PSN1 M4jxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7jbHQyUUN3ME2xMlUxPjd4IN88US=> NYrWZpl6W0GQR1XS
SR NEX3WW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDaUY5KSzVyPUGuOVQ2PzJizszN M3zSU3NCVkeHUh?=
A3-KAW Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXVTWM2OD1zLk[yOVQ3KM7:TR?= MXvTRW5ITVJ?
KS-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX6xOoNNUUN3ME2xMlY6OjR5IN88US=> M3fKe3NCVkeHUh?=
CTV-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUSxemNxUUN3ME2xMlczPzVzIN88US=> NG[xVm5USU6JRWK=
LB1047-RCC NX\Q[YVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXLcWpnUUN3ME2xMlgyPjJ2IN88US=> M4KycnNCVkeHUh?=
EMG-01 MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\COlBrUUN3ME2xMlg{PTZ|IN88US=> Ml76V2FPT0WU
TE-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX0SIFKSzVyPUGuPFM6QDVizszN MoTwV2FPT0WU
CMK M1jiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTiTWM2OD1zLkm1OVE4KM7:TR?= NGj4UJJUSU6JRWK=
NB1 M1fVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn6PJFKSzVyPUGuPVYyOTdizszN NXq5[2hLW0GQR1XS
HAL-01 NWXKVmxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3i2eWlEPTB;Mj6wOVk1PiEQvF2= M4HaV3NCVkeHUh?=
DEL NYfxboZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\YTWM2OD1{LkC4OFgzKM7:TR?= NWDPZWxFW0GQR1XS
RL95-2 MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLHTWM2OD1{LkGxNVM4KM7:TR?= NVLvS3BmW0GQR1XS
KARPAS-299 M3zNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\EOWlEPTB;Mj6xNVMyOyEQvF2= NVTWdnpZW0GQR1XS
EW-16 NXPifppKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLTbXBKSzVyPUKuNVM2ODhizszN NIDKdZlUSU6JRWK=
RS4-11 M2rzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO0d2V1UUN3ME2yMlE4QTJ2IN88US=> MUXTRW5ITVJ?
BB30-HNC M2Cx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJwMkKzO|Uh|ryP NHvhPIZUSU6JRWK=
DOHH-2 NIHCWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG5TWM2OD1{LkOzOFMyKM7:TR?= NV3rfZBxW0GQR1XS
RPMI-8402 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\3O2lEPTB;Mj6zN|YyQCEQvF2= NFHWRZVUSU6JRWK=
BV-173 NYL3ZnptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13CcGlEPTB;Mj6zN|Y3KM7:TR?= M2rzfHNCVkeHUh?=
TE-10 M4PVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r0XmlEPTB;Mj6zOFM5PCEQvF2= Ml61V2FPT0WU
TE-8 NGjTOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDxZW5KSzVyPUKuN|cxOzhizszN Mn;HV2FPT0WU
K052 M3nHTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr1ZlhKSzVyPUKuOFAzODJizszN M1rEXXNCVkeHUh?=
KARPAS-45 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJwNEm0OFYh|ryP NX:1ZpNmW0GQR1XS
SK-NEP-1 Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJwNkCyN|ch|ryP NH\NfpZUSU6JRWK=
KGN NYfGXG5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;GTWM2OD1{Lk[wN|M6KM7:TR?= MVHTRW5ITVJ?
ML-2 M3L2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJwNkO1NVIh|ryP NYfiXpZYW0GQR1XS
LAMA-84 M{XYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\wbGlEPTB;Mj62PVU1PSEQvF2= MmTMV2FPT0WU
LXF-289 M1;zNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7KO|dWUUN3ME2yMlczQTh7IN88US=> M1HnSXNCVkeHUh?=
A101D MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT2TWM2OD1{Lke4N|A1KM7:TR?= NEWyRYFUSU6JRWK=
KY821 NV3PZYNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV36[3RRUUN3ME2yMlc6PzV6IN88US=> Mn\WV2FPT0WU
ES4 M{PrNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXaN5ZUUUN3ME2yMlgxPjJ6IN88US=> MnzlV2FPT0WU
SCC-3 NX;DcZVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJwOEK4PVEh|ryP NUHE[JBwW0GQR1XS
NALM-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPOTWM2OD1{LkmwOFc{KM7:TR?= MoLTV2FPT0WU
BL-41 M2\mOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Pn[GlEPTB;Mj65NVIzOiEQvF2= MmrMV2FPT0WU
OPM-2 MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTNwMEW5OVQh|ryP M1rOW3NCVkeHUh?=
SF126 M2nYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFewT2dKSzVyPUOuNFYyQThizszN NUDhZXNJW0GQR1XS
BE-13 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPYZpRKSzVyPUOuNlMyOTFizszN M1PUS3NCVkeHUh?=
SF268 MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDZTWM2OD1|LkOyPFY6KM7:TR?= NEfCblhUSU6JRWK=
MOLT-4 Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7rOWJKSzVyPUOuN|k5OzhizszN NULKOXNvW0GQR1XS
PF-382 MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\3dWRjUUN3ME2zMlQ1PTdizszN M3;RRnNCVkeHUh?=
HEL M2\ETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvuUnRGUUN3ME2zMlQ5ODB3IN88US=> NGHJc|RUSU6JRWK=
RPMI-6666 NHXxd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjtRol3UUN3ME2zMlU1OTdzIN88US=> MnvpV2FPT0WU
QIMR-WIL M4HLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNwNkOzPVEh|ryP M4rme3NCVkeHUh?=
ATN-1 NHjLWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q5NWlEPTB;Mz62O|EyPCEQvF2= NF:ySHlUSU6JRWK=
BB49-HNC NVrWUJVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HoOGlEPTB;Mz63NFUxQCEQvF2= MljPV2FPT0WU
HCE-4 NXG2boVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTNwN{i2OFIh|ryP MV7TRW5ITVJ?
SK-LMS-1 NXP3S5V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\3eWVKSzVyPUOuPFM{OzhizszN NYjs[o52W0GQR1XS
MS-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i2U2lEPTB;Mz64N|c4QCEQvF2= NWLHZ5oyW0GQR1XS
JAR MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;x[olKSzVyPUOuPVg5OzJizszN M3i0NnNCVkeHUh?=
KE-37 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXBNVNKSzVyPUSuNFYyPThizszN NXn2RYVzW0GQR1XS
LB996-RCC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m2dGlEPTB;ND6xNlE3QCEQvF2= NFLze|JUSU6JRWK=
HH NISxblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHrS|Z2UUN3ME20MlIxQTF2IN88US=> MU\TRW5ITVJ?
HL-60 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTMTWM2OD12LkKxNFY2KM7:TR?= MXXTRW5ITVJ?
HOP-62 M2DLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{npT2lEPTB;ND6zN|UzKM7:TR?= NV3XPHR5W0GQR1XS
NOMO-1 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[weWdKSzVyPUSuN|M3QTlizszN M4DZV3NCVkeHUh?=
DU-4475 M3;Udmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTRwM{[3Nlkh|ryP M3LMV3NCVkeHUh?=
LC4-1 M4f4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TueGlEPTB;ND6zPFA4KM7:TR?= MVrTRW5ITVJ?
MC116 NVPTfY17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTRwNEOwPFEh|ryP NUT6W2hPW0GQR1XS
SW982 NEPPd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTRwNUWzNFch|ryP NYC3bItyW0GQR1XS
SK-N-DZ MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvxfGhKSzVyPUSuOlcxQTlizszN NWX4NGl7W0GQR1XS
EW-1 M1jzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXjXXdKSzVyPUSuOlc6OTFizszN M4TNcXNCVkeHUh?=
SU-DHL-1 NWnFU2dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT4TWM2OD12LkiwNVc1KM7:TR?= NInURYRUSU6JRWK=
L-363 NVzCPHA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRwOEC2NlEh|ryP M1K0V3NCVkeHUh?=
OS-RC-2 NITSfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HNOmlEPTB;ND64O|MyKM7:TR?= MnK5V2FPT0WU
HD-MY-Z NFO0bm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknoTWM2OD13LkG3N|AyKM7:TR?= MXjTRW5ITVJ?
MHH-PREB-1 NXn5SWhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\I[GlEPTB;NT6zNlMyOiEQvF2= NIO2b21USU6JRWK=
HC-1 NH3CNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoexTWM2OD13LkSzNlkyKM7:TR?= MoK0V2FPT0WU
SK-MM-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTVwNEe4NkDPxE1? M4W5RXNCVkeHUh?=
SH-4 M4T4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHviN5hKSzVyPUWuOFg{PyEQvF2= M1;rW3NCVkeHUh?=
MHH-CALL-2 M4Czb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPmT4tKSzVyPUWuO|Y4OTlizszN MXPTRW5ITVJ?
KG-1 NILRPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX2eIk5UUN3ME22MlAzQDd6IN88US=> MkH6V2FPT0WU
J-RT3-T3-5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37YVGlEPTB;Nj6wO|kxQSEQvF2= Mo\YV2FPT0WU
MMAC-SF NELwT5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTZwMUC5OFkh|ryP NWnGVYxjW0GQR1XS
IST-SL2 M2DjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;oVmlEPTB;Nj6xNlUyQSEQvF2= NI\l[49USU6JRWK=
SW954 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;rTWM2OD14LkK3OVE4KM7:TR?= NEPkeYFUSU6JRWK=
HDLM-2 NEO5TYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLDW3lKSzVyPU[uN|IyODlizszN MV;TRW5ITVJ?
ST486 Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUmzcXNMUUN3ME22MlM1PzFizszN NHT6dVZUSU6JRWK=
DG-75 NIfFUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfUTWM2OD14LkSzNFY6KM7:TR?= NImwUpJUSU6JRWK=
EW-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTZwNEOyNFch|ryP MlLDV2FPT0WU
8-MG-BA MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnOwTWM2OD14LkWxOVA4KM7:TR?= M3rLc3NCVkeHUh?=
GT3TKB M3XWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTZwNkC3OlMh|ryP MX;TRW5ITVJ?
KU812 NIPweFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXITWM2OD14Lk[5OFIh|ryP MYXTRW5ITVJ?
CESS NWTReplTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPOR5NxUUN3ME23MlExPDN6IN88US=> MULTRW5ITVJ?
BC-1 NXfsd5Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPtTWM2OD15LkK0PFEzKM7:TR?= MWDTRW5ITVJ?
MZ1-PC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uzWGlEPTB;Nz6zNFM5QSEQvF2= NUnic4F4W0GQR1XS
NCI-H82 MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLyTWM2OD15LkO3PFUh|ryP MYHTRW5ITVJ?
NCI-H1355 M4ToW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXKflNKSzVyPUeuOFU5ODRizszN MWHTRW5ITVJ?
RPMI-8226 NF\heWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K0R2lEPTB;Nz61NFc{QSEQvF2= MnnlV2FPT0WU
ARH-77 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTdwNUO1PVch|ryP NYC1RYtuW0GQR1XS
MN-60 M1LzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7scFEyUUN3ME23MlU1ODh6IN88US=> NXWyS3gzW0GQR1XS
IMR-5 MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDuTWM2OD15MEW0PFc3KM7:TR?= MlK0V2FPT0WU
KARPAS-422 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO0TWM2OD15LkW3NlA3KM7:TR?= NF3OUmpUSU6JRWK=
CA46 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPu[mJKSzVyPUeuOVgxOTJizszN MnvYV2FPT0WU
SJSA-1 NH[4bVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLnT2FjUUN3ME23MlY3ODZzIN88US=> M4\GVnNCVkeHUh?=
no-11 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTdwN{e1OVch|ryP MULTRW5ITVJ?
IST-SL1 NG\0VYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon1TWM2OD16LkCyOFE4KM7:TR?= MX3TRW5ITVJ?
NCI-H209 NUfa[|RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vZSWlEPTB;OD6xNVY2OiEQvF2= NGXyc45USU6JRWK=
TALL-1 NYDBZplXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LpZmlEPTB;OD6xPFM5PCEQvF2= M{P2[HNCVkeHUh?=
KMOE-2 NGO4[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnz[3g{UUN3ME24MlE6PDJizszN M1LzVnNCVkeHUh?=
HCC1599 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LNbmlEPTB;OD6xPVk5PyEQvF2= M3zzNnNCVkeHUh?=
CI-1 NIXrO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jJOmlEPTB;OD6yNFQyOSEQvF2= MVPTRW5ITVJ?
NCI-H1304 NHvFSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPSTWM2OD16LkKwOlYyKM7:TR?= MmG5V2FPT0WU
Daudi MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\rVGlEPTB;OD6yN|U1PiEQvF2= MV\TRW5ITVJ?
CPC-N MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;wTWM2OD16LkK5NVk6KM7:TR?= MoXFV2FPT0WU
MC-CAR M1rsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfIephwUUN3ME24MlM{PThizszN MUTTRW5ITVJ?
SW872 M3LpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;kWGlEPTB;OD6zOFc2QCEQvF2= NVOwT3JjW0GQR1XS
OVCAR-4 M17DSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rMWmlEPTB;OD61NFM2OSEQvF2= NVfCdHhjW0GQR1XS
OCUB-M M4q1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPiTWM2OD16LkW2OVA5KM7:TR?= MojZV2FPT0WU
SK-PN-DW MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrXTWM2OD16Lk[wPVg2KM7:TR?= MUfTRW5ITVJ?
NCCIT Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRThwN{G3OFUh|ryP NXfnSnNLW0GQR1XS
NCI-H1648 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTwdYttUUN3ME25MlE{QDN2IN88US=> MnfSV2FPT0WU
COR-L279 NHXmTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TIcWlEPTB;OT6zPVA6KM7:TR?= NWnzVpNpW0GQR1XS
LS-123 MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3WTWM2OD17Lk[4NVYyKM7:TR?= MoXoV2FPT0WU
LP-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTlwN{iwPFMh|ryP MmPvV2FPT0WU
NB13 M{Hwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vLRWlEPTB;OT63PVk6PCEQvF2= NYD4d4dYW0GQR1XS
ONS-76 M4Hy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3joU2lEPTB;OT64NVAyPiEQvF2= NYjCfG9rW0GQR1XS
VA-ES-BJ NEjlPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTlwOUm5N|Mh|ryP NV;GPVBsW0GQR1XS
GR-ST NYX5UYViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLjfFNKSzVyPUGwMlIzODdizszN MkXVV2FPT0WU
ES1 Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXtRWJEUUN3ME2xNE4zQTh2IN88US=> NXLvfGR{W0GQR1XS
NB14 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XEd2lEPTB;MUCuPVI4PyEQvF2= MYPTRW5ITVJ?
Ramos-2G6-4C10 NWXVSZd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K4W2lEPTB;MUGuNlY2KM7:TR?= M2nPTnNCVkeHUh?=
RXF393 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTFzLkS4N|Qh|ryP NFLueXRUSU6JRWK=
NCI-H2107 NIHJ[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\BU2lEPTB;MUGuOVk5PCEQvF2= NYjlb2d7W0GQR1XS
K562 NVXXUIZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFzLki3NFIh|ryP MXLTRW5ITVJ?
LOUCY NEDXTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfm[ZpTUUN3ME2xNU46QDd3IN88US=> MX\TRW5ITVJ?
TGBC1TKB NVziZopLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofzTWM2OD1zMj6wNFIh|ryP M3TxUXNCVkeHUh?=
COLO-320-HSR MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOySlRKSzVyPUGyMlE2PjVizszN MlXHV2FPT0WU
K5 NHjWO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXrTWM2OD1zMj6yPVg2KM7:TR?= NYi5To5IW0GQR1XS
BC-3 NVzFUYc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF{LkS2OVEh|ryP NEjYPXBUSU6JRWK=
REH MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHrVY1KSzVyPUGyMlY1QThizszN Mn3OV2FPT0WU
NEC8 MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvNRYtnUUN3ME2xNk43QDh5IN88US=> MnzuV2FPT0WU
IST-MEL1 NXfoXlNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLiTWM2OD1zMj64Olk1KM7:TR?= NHe5S4VUSU6JRWK=
NCI-H128 Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXpPI5MUUN3ME2xN{4xPzJ|IN88US=> NH\wXJZUSU6JRWK=
NCI-H1694 MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG1OIxKSzVyPUGzMlEyPDRizszN MYnTRW5ITVJ?
TGW MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfXOHRiUUN3ME2xN{4{Ojd4IN88US=> NETSPGJUSU6JRWK=
NCI-SNU-1 NX;GR4pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIW2c2pKSzVyPUGzMlM1PSEQvF2= MUXTRW5ITVJ?
IST-MES1 M{PnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF|Lk[3Nlkh|ryP NVXXd4hPW0GQR1XS
CTB-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjrTWM2OD1zMz63Nlk1KM7:TR?= MkLGV2FPT0WU
HUTU-80 M3P3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXsSXZKSzVyPUGzMlc2PzNizszN MnHWV2FPT0WU
LAN-6 M1jLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fBXGlEPTB;MUSuNlQ2PyEQvF2= NHLVUWxUSU6JRWK=
KP-N-YS MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1roZWlEPTB;MUSuNlg6PCEQvF2= NEizXGdUSU6JRWK=
CCRF-CEM M{nRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF2LkSxOlkh|ryP MkLIV2FPT0WU
NCI-H1770 M1KwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITnVJpKSzVyPUG0MlU{PjlizszN NGnySVVUSU6JRWK=
MZ2-MEL NV3KboxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF3LkKyOVEh|ryP MX3TRW5ITVJ?
COR-L88 M3;xcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfkemFsUUN3ME2xOk4xODF{IN88US=> MX;TRW5ITVJ?
LOXIMVI Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHaR5ZKSzVyPUG2MlI2PiEQvF2= MonYV2FPT0WU
KALS-1 NX63U|BwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTVXFNjUUN3ME2xOk42QTNzIN88US=> MV3TRW5ITVJ?
D-283MED MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DTTGlEPTB;MU[uPFQ5QSEQvF2= M{TubHNCVkeHUh?=
NCI-H719 M2LXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;IbWlEPTB;MU[uPVE3OSEQvF2= M2L2eHNCVkeHUh?=
MLMA NF7ifZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDJbIF4UUN3ME2xOk46QTB5IN88US=> M2nFTnNCVkeHUh?=
EVSA-T M1LtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XsRmlEPTB;MUeuNFQ5PSEQvF2= NFPQclBUSU6JRWK=
SK-N-FI M172Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;EdG1KSzVyPUG3MlY6OTNizszN NG\OXWFUSU6JRWK=
NTERA-S-cl-D1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTF5Lki1O|Ih|ryP MWnTRW5ITVJ?
NCI-H1882 MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF5Lkm4N|Qh|ryP MWHTRW5ITVJ?
A704 MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rWOWlEPTB;MUeuPVkxPCEQvF2= M2T0b3NCVkeHUh?=
L-428 NHTlSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16zVmlEPTB;MUiuNFE2OSEQvF2= NFK4emZUSU6JRWK=
HCC1187 NG\YcHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF6LkCxPFch|ryP NWHQ[2tGW0GQR1XS
NCI-H1581 NEXGXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n2VWlEPTB;MUiuNFg3PiEQvF2= Mm\iV2FPT0WU
BB65-RCC Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\nSpFKSzVyPUG4MlQyPjJizszN NW\pdmVIW0GQR1XS
EM-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr2dVhKSzVyPUG4MlU3PzJizszN NVjJS5I{W0GQR1XS
Raji M4TWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;LTWM2OD1zOT65OVY2KM7:TR?= NFLr[VdUSU6JRWK=
TE-1 NUXvXVU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[1TWM2OD1{MD60NVA1KM7:TR?= MoL4V2FPT0WU
SW962 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEToPJhKSzVyPUKwMlQzQTNizszN MoTPV2FPT0WU
MHH-NB-11 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DRNGlEPTB;MkCuOVUzOSEQvF2= MXLTRW5ITVJ?
no-10 MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJzLkCyOlQh|ryP NE\nSoJUSU6JRWK=
GDM-1 NIK5SWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HoSmlEPTB;MkGuPVQyPCEQvF2= MVLTRW5ITVJ?
KMS-12-PE M3r4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJ{LkK3OEDPxE1? MYTTRW5ITVJ?
NCI-H510A NFPDR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ2LkGyO|gh|ryP NXLDR2x5W0GQR1XS
ES5 M1zOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF2zc5JKSzVyPUK0Mlc{PDlizszN M{\OcXNCVkeHUh?=
JiyoyeP-2003 MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT4R5FKSzVyPUK2MlI4PDJizszN MWTTRW5ITVJ?
NMC-G1 NIPieZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT6TWM2OD1{Nz6xPFIzKM7:TR?= MkjVV2FPT0WU
NCI-H446 NFXLSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHix[ZJKSzVyPUK3MlQ6PDZizszN NXO2U2luW0GQR1XS
NB7 NGTFdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MortTWM2OD1{Nz65NlI6KM7:TR?= MofQV2FPT0WU
A388 NUjkeZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz4fI86UUN3ME2yPE4xODd2IN88US=> M1;aSXNCVkeHUh?=
JVM-2 NF3QXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJ6LkK4PVgh|ryP MWfTRW5ITVJ?
HT-144 M2nmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz2SYFKSzVyPUK4MlY6KM7:TR?= M3\MfXNCVkeHUh?=
NCI-H747 M4Tvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJ6LkmxPVUh|ryP NVe3PHB4W0GQR1XS
NCI-H1650 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TTbmlEPTB;MkmuNFE4PiEQvF2= NG\TcYVUSU6JRWK=
EB-3 M3TQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M172OGlEPTB;MkmuOVMxQSEQvF2= NVHvcGhYW0GQR1XS
KLE M3H0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;QTmJVUUN3ME2yPU43OTlizszN M37B[HNCVkeHUh?=
TK10 NYfCVooyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfLTWM2OD1|MD6xNlYh|ryP MlHmV2FPT0WU
COLO-668 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;6e2hMUUN3ME2zNE44QTJizszN MljXV2FPT0WU
NCI-H23 NHzMN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nTWWlEPTB;M{GuNVA3OyEQvF2= MV3TRW5ITVJ?
GOTO M{DFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\pTWM2OD1|MT62NFg2KM7:TR?= NXHHXmk6W0GQR1XS
MSTO-211H MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXVTWM2OD1|MT64Olc5KM7:TR?= NV[0T|VIW0GQR1XS
LB831-BLC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXhTWM2OD1|Mj6zPFQ{KM7:TR?= M4T1[HNCVkeHUh?=
SCH NWHucmhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLadnNKSzVyPUOyMlg1QDVizszN NEfMOoRUSU6JRWK=
EHEB NF7vTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHixW2JKSzVyPUO0MlEyQTNizszN NI[4UWNUSU6JRWK=
U-266 NFPY[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\1dmlEPTB;M{SuNlc5OSEQvF2= MmfaV2FPT0WU
EW-11 NXjzWY5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXflemlSUUN3ME2zOE41PzJ3IN88US=> NELu[IFUSU6JRWK=
TE-9 M3;jeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTN5LkC0NFEh|ryP M2KwTXNCVkeHUh?=
ES3 M3\YVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;ieWlEPTB;M{euOVAxPCEQvF2= MVXTRW5ITVJ?
NCI-H2141 NH\pVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTN6LkC4OFMh|ryP NFfRfFNUSU6JRWK=
MPP-89 M2TIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTR{LkC1PFYh|ryP NFPYWnZUSU6JRWK=
SK-MEL-2 NIr3UXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HwVmlEPTB;NEKuOlQxPSEQvF2= MVzTRW5ITVJ?
LC-1F Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXVNGFDUUN3ME20N{4{Pjh{IN88US=> MV3TRW5ITVJ?
NH-12 NULNZYg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7zN2xKSzVyPUSzMlk{PTlizszN MoTuV2FPT0WU
RKO NVr4Z2x[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LTPGlEPTB;NESuNVI2OiEQvF2= NWf3[ndmW0GQR1XS
KM-H2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljYTWM2OD12ND65OVc4KM7:TR?= MkLWV2FPT0WU
SK-UT-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTR7Lki4NlUh|ryP NIr5NpJUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
+ Expand
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Formulation: Formulated as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
4% DMSO+30% PEG 300+ddH2O
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02761057 Recruiting Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma National Cancer Institute (NCI) April 2016 Phase 2
NCT02779283 Recruiting Untreated Adult Acute Myeloid Leukemia OHSU Knight Cancer Institute|National Cancer Institute (NCI) December 2015 Phase 1
NCT02626754 Enrolling by invitation Renal Cell Carcinoma vghtpe user|Taipei Veterans General Hospital, Taiwan August 2015 Phase 2
NCT02465060 Recruiting Advanced Malignant Neoplasm|Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Solid Neoplasm|Refractory Malignant Neoplasm|Refractory Plasma Cell Myeloma National Cancer Institute (NCI) August 2015 Phase 2
NCT01835158 Active, not recruiting Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Cancer|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer National Cancer Institute (NCI) July 2013 Phase 2
NCT01740154 Terminated Fatigue|Recurrent Renal Cell Cancer|Stage IV Renal Cell Cancer Case Comprehensive Cancer Center|National Cancer Institute (NCI) September 2012 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was wondering that the compound is in its cis or trans form?

  • Answer:

    S1042 Sunitinib Malate is Z form.

  • Question 2:

    What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?

  • Answer:

    S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

Related Antibodies

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID